Open an account

Dare Bioscience

DARE · NASDAQ

$0.689+$0.0207 (+3.10%)TodayMarket closed ·
Prev close $0.6683

About DARE

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

Employees
23
Headquarters
San Diego, California
Listed
Apr 10, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
darebioscience.com

DARE key statistics

Market cap
13.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
185.13K
Volume
1
Open price
$0.71
High today
$0.7297
Low today
$0.67
52 Week high
$3.78
52 Week low
$0.68

Dare Bioscience (DARE) at a glance

As of Oct 21, 2026, Dare Bioscience (DARE) shares are priced at $0.689, giving the company a market cap of 13.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.67 and $0.7297. The current price is 2.8% above the day's low and 5.6% below its high.

Volume so far is 1 shares, below the average of 185.13K shares a day.

Over the past year Dare Bioscience has ranged from $0.68 to $3.78, and now sits 0% of the way up that range.

Dare Bioscience met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.2499.

The average analyst price target is $8.50, 1133.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $8.50
Low
$5.05
Now
$0.689
High
$12.60

DARE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 33.8% on average.

  1. Q3 FY24: reported -$0.55 per share against an estimate of -$0.748
  2. Q4 FY24: reported -$0.65 per share against an estimate of -$0.544
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$0.5916
  4. Q2 FY25: reported -$0.45 per share against an estimate of -$0.5916
  5. Q3 FY25: reported -$0.28 per share against an estimate of -$0.3638
  6. Q4 FY25: reported -$0.02 per share against an estimate of -$0.4412
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.2958
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.2499

DARE news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

  • Press releaseGlobe Newswire

    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

  • Press releaseGlobe Newswire

    Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Vandana Singh

    Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

Similar companies

Companies in the same industry as Dare Bioscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.